The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.
Aged between 18 and 60 years old;
Acute myeloid leukemia (AML, AML subtype M3 excluded) diagnosed according to the 2022 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, who have achieved complete remission (CR1) and are going to receive consolidation therapy (cytarabine or cytarabine-based combined regimen, the cycle of consolidation therapy is not limited);
The participant or his/her legal guardian is adequately informed of the nature and risks of the study, voluntarily participates in the study with signed informed consent;
Male or female;
Central nervous system manifestations of acute myeloid leukemia at diagnosis;
Secondary acute myeloid leukemia;
Myelosuppression induced by conditions other than anti-cancer therapy;
Previous radiation therapy performed on sternum or pelvis;